Thursday - December 11, 2025

Category Archives: Business

Post Traumatic Stress Disorder Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Pfizer, GlaxoSmithKline, KGK Science Inc., AstraZeneca, UCB Pharma, Bionorica SE, Bionomics Ltd

The Key Post Traumatic Stress Disorder Companies in the market include – Nobilis Therapeutics, Otsuka Pharma, Compass Pathways, Aptinyx, Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, GlaxoSmithKline, KGK Science Inc., AstraZeneca, UCB Pharma, Bionorica SE, Bionomics Limited, Pfizer, and … Continue reading →

Sarcopenia Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross

The Key Sarcopenia Companies in the market include – TNF Pharmaceuticals, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirscience Therapeutics, Turn Biotechnologies, NMD PHARMA, ImmunoForge, Dong Wha PHARM, and others.   DelveInsight’s “Sarcopenia Market Insights, Epidemiology, and Market … Continue reading →

Ovarian Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact Therap

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Ovarian Cancer pipeline constitutes 180+ key companies continuously working towards developing 200+ Ovarian Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Actinium Pharmaceuticals Advances Trop-2 Targeted Alpha Radiotherapy Into Phase 1/2 Trials in the U.S. and Australia

Actinium Pharmaceuticals (NYSE American: ATNM) is advancing its Trop-2–targeted ATNM-400 construct into Phase 1/2 trials across the United States and Australia, marking an important step as the company broadens its presence in solid-tumor radiopharmaceuticals. With targeted alpha radiotherapy gaining momentum … Continue reading →

Mucopolysaccharidosis Type I Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | BioMarin Pharma, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharma, Nippon Shinyaku

The Key Mucopolysaccharidosis Type I Companies in the market include – BioMarin Pharmaceutical, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharmaceuticals, Nippon Shinyaku, Immusoft, Genevector Biotechnology, EdiGene Inc., REGENXBIO, Sigilon Therapeutics, Paradigm Biopharma, Jupiter Neurosciences, and others.   DelveInsight’s “Mucopolysaccharidosis Type … Continue reading →

Holiday Skin Stress? KREMOLOGIE™ Offers Professional Solutions for Sensitive, Aging Skin This Season

“The holidays wreak havoc on sensitive skin, but women shouldn’t have to choose between enjoying the season and maintaining healthy skin. KREMOLOGIE gives them professional-strength support when they need it most,” says the KREMOLOGIE spokesperson. Professional-grade skincare brand KREMOLOGIE addresses … Continue reading →